Latest From Ipsen
Liposomal chemotherapy drug Onivyde achieved a 44% response rate in second-line small cell lung cancer patients, providing preliminary validation of its ability to improve outcomes in the hard-to-treat disease.
Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.
Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.
Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...
- OTC, Consumer
- Specialty Pharmaceuticals
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Beaufour Ipsen
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Senior Management
David Meek, CEO
Aymeric Le Chatelier, EVP, Fin. & CFO
Alexandre Lebeaut, MD, EVP, R&D & CSO
Ivana Magovcevic-Liebisch, EVP, CBO
- Contact Info
Phone: (33) 1 58 33 50 00
65 Quai George Gorse
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.